Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ROS1 | P08922 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 5/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 2/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 3/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16184374 | 0.93 | NPC1 (0.44) | NPC1RAB9AROS1ABL1LIMK1 | |
| SCHEMBL16184365 | 0.91 | FEN1 (0.41) | NPC1RAB9AALOX5APFEN1CLK1 | |
| SCHEMBL16184372 | 0.89 | CYP1A2 (0.42) | NPC1RAB9ALIMK1MAPK14ALOX5AP | |
| SCHEMBL16184367 | 0.89 | NPC1 (0.39) | NPC1RAB9AABL1ALOX5APFEN1 | |
| SCHEMBL16184382 | 0.87 | MAT2A (0.39) | NPC1RAB9AALOX5APFEN1CLK1 | |
| SCHEMBL16184364 | 0.86 | LATS1 (0.37) | NPC1RAB9AALOX5APFEN1LATS1 | |
| SCHEMBL16184375 | 0.86 | TGFBR1 (0.41) | NPC1RAB9AALOX5APFEN1MAT2A | |
| SCHEMBL16184379 | 0.85 | NPC1 (0.36) | NPC1RAB9AALOX5APFEN1MAT2A | |
| SCHEMBL16184408 | 0.85 | CYP1A2 (0.48) | RAB9AROS1MAPK14CLK1 | |
| SCHEMBL16184373 | 0.85 | NPC1 (0.36) | NPC1RAB9AABL1LIMK1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | NPC1 2208/4885RAB9A 1340/4885ROS1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.